{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:29:01Z","timestamp":1767677341049,"version":"3.48.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260914"],"award-info":[{"award-number":["82260914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260798"],"award-info":[{"award-number":["82260798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460802"],"award-info":[{"award-number":["82460802"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, has transformed treatment for chronic myeloid leukemia and Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. However, its broad kinase inhibition leads to distinct adverse events (AEs), requiring systematic post-marketing surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate dasatinib-associated AEs using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and identify potential safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted FAERS reports (Q1 2004\u2013Q4 2024) listing dasatinib as the primary suspect drug, submitted by physicians or pharmacists. After data cleaning, AEs were coded using MedDRA terminology. Signal detection was performed with four disproportionality methods (ROR, PRR, BCPNN, MGPS). Time-to-onset was analyzed using Weibull models, with subgroup analyses by demographic and clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 7,213 cases, respiratory disorders were the most prominent signal (ROR = 2.74). A total of 1,951 significant signals were identified, 113 confirmed by all algorithms. Strongest disproportionality signals included blast cell proliferation (ROR = 518.94), primary effusion lymphoma (ROR = 181.38), and allogeneic bone marrow transplantation therapy (ROR = 171.48). Common AEs were pleural effusion (\n                      <jats:italic>n<\/jats:italic>\n                      = 828, ROR = 35.87), hepatotoxicity (\n                      <jats:italic>n<\/jats:italic>\n                      = 262, ROR = 29.17), and fluid retention (\n                      <jats:italic>n<\/jats:italic>\n                      = 129, ROR = 14.49). Weibull analysis showed an early failure pattern (\u03b2 = 0.64), with 25.6% of AEs within 30 days and 28.2% after 360 days. Subgroup analysis revealed pleural effusion across all demographics, while hematologic signals predominated in adults and elderly patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large FAERS analysis characterized known respiratory complications of dasatinib, particularly pleural effusion, and identified several rare but potentially relevant safety signals hepatotoxicity, cardiovascular events, and novel AEs such as alveolar proteinosis and cytomegalovirus-related complications. The early failure pattern underscores the need for intensive monitoring during initiation and continued vigilance during long-term therapy. These findings provide real-world, hypothesis-generating evidence to optimize safety management and inform future clinical investigations, and should be interpreted with caution in view of the inherent limitations of spontaneous reporting data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1709089","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:19:54Z","timestamp":1767676794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhen","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1002\/hem3.56","article-title":"Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors.","volume":"8","author":"Komorowski","year":"2024","journal-title":"Hemasphere."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.3390\/ijms21165776","article-title":"Philadelphia chromosome-positive leukemia in the lymphoid lineage-similarities and differences with the myeloid lineage and specific vulnerabilities.","volume":"21","author":"Komorowski","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"key":"B4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017.","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1741-7015-9-99","article-title":"Advances in the treatment of chronic myeloid leukemia.","volume":"9","author":"Eiring","year":"2011","journal-title":"BMC Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/OTT.S35360","article-title":"Systematic review of dasatinib in chronic myeloid leukemia.","volume":"6","author":"Breccia","year":"2013","journal-title":"Onco Targets Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","article-title":"Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.","volume":"99","author":"Chang","year":"2008","journal-title":"Br J Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib.","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1700217","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-024-01430-8","article-title":"Timing matters: a machine learning method for the prioritization of drug-drug interactions through signal detection in the FDA adverse event reporting system and their relationship with time of co-exposure.","volume":"47","author":"Battini","year":"2024","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia.","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood.V112.11.4290.4290","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia.","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors.","volume":"125","author":"Valent","year":"2015","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia."},{"key":"B22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/bmt.2012.241","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis.","volume":"48","author":"Bergeron","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy.","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic Myeloid Leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"Shah","year":"2004","journal-title":"Science."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00109-011-0814-7","article-title":"Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.","volume":"90","author":"Morgan","year":"2012","journal-title":"J Mol Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review.","volume":"93","author":"Yang","year":"2015","journal-title":"Crit Rev Oncol Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst."},{"key":"B34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature."},{"key":"B35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia.","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."},{"key":"B39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia.","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.","volume":"122","author":"Ross","year":"2013","journal-title":"Blood."},{"key":"B51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term follow-up of the french Stop imatinib (STIM1) study in patients with chronic myeloid leukemia.","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1709089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:19:55Z","timestamp":1767676795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1709089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":52,"alternative-id":["10.3389\/fmed.2025.1709089"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1709089","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1709089"}}